MX2022009169A - Composiciones y metodos para tratar y prevenir hepatitis b y d. - Google Patents

Composiciones y metodos para tratar y prevenir hepatitis b y d.

Info

Publication number
MX2022009169A
MX2022009169A MX2022009169A MX2022009169A MX2022009169A MX 2022009169 A MX2022009169 A MX 2022009169A MX 2022009169 A MX2022009169 A MX 2022009169A MX 2022009169 A MX2022009169 A MX 2022009169A MX 2022009169 A MX2022009169 A MX 2022009169A
Authority
MX
Mexico
Prior art keywords
hepatitis
compositions
methods
treating
combinations
Prior art date
Application number
MX2022009169A
Other languages
English (en)
Spanish (es)
Inventor
MATTI SäLLBERG
Lars Frelin
Original Assignee
Svenska Vaccinfabriken Produktion Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Svenska Vaccinfabriken Produktion Ab filed Critical Svenska Vaccinfabriken Produktion Ab
Publication of MX2022009169A publication Critical patent/MX2022009169A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
    • C12N2760/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
MX2022009169A 2020-01-28 2021-01-26 Composiciones y metodos para tratar y prevenir hepatitis b y d. MX2022009169A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062966970P 2020-01-28 2020-01-28
PCT/US2021/015126 WO2021154752A1 (en) 2020-01-28 2021-01-26 Compositions and methods for treating and preventing hepatitis b and d

Publications (1)

Publication Number Publication Date
MX2022009169A true MX2022009169A (es) 2022-12-08

Family

ID=74673345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009169A MX2022009169A (es) 2020-01-28 2021-01-26 Composiciones y metodos para tratar y prevenir hepatitis b y d.

Country Status (9)

Country Link
US (1) US20230079898A1 (cg-RX-API-DMAC7.html)
EP (1) EP4096711A1 (cg-RX-API-DMAC7.html)
JP (1) JP7855515B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220149519A (cg-RX-API-DMAC7.html)
CN (1) CN115335075A (cg-RX-API-DMAC7.html)
AU (1) AU2021214939A1 (cg-RX-API-DMAC7.html)
CA (1) CA3169407A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009169A (cg-RX-API-DMAC7.html)
WO (1) WO2021154752A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101564533B (zh) * 2009-06-12 2012-01-04 东南大学 戊型肝炎蛋白-核酸复合疫苗及其制备方法
CN102895659B (zh) * 2011-07-29 2014-10-29 复旦大学 一种防治老年痴呆症复合疫苗及其制备方法
US10905760B2 (en) 2016-01-28 2021-02-02 Svenska Vaccinfabriken Produktion Ab Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines containing hepatitis B virus genes
AU2017332854B2 (en) * 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
JP7855515B2 (ja) 2026-05-08
AU2021214939A1 (en) 2022-09-15
KR20220149519A (ko) 2022-11-08
CN115335075A (zh) 2022-11-11
JP2023512526A (ja) 2023-03-27
CA3169407A1 (en) 2021-08-05
EP4096711A1 (en) 2022-12-07
US20230079898A1 (en) 2023-03-16
WO2021154752A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
MX2022009836A (es) Vacuna para sars-cov-2.
HRP20201873T1 (hr) Sredstva i postupci za liječenje hbv-a
GB2574561A (en) Engineering CRISPR CAS9 immune stealth
WO2021222639A3 (en) Recombinant human metapneumovirus f proteins and their use
EP4599847A3 (en) Prefusion coronavirus spike proteins and their use
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
JP2016128513A5 (cg-RX-API-DMAC7.html)
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
EA202090759A3 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
WO2020065349A3 (en) Vaccines and methods
FI3737397T3 (fi) Prameen kohdistetut syöpärokotteet ja niiden käytöt
RU2018123307A (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака
MX2021002147A (es) Tratamiento de la infección por virus de la hepatitis delta con interferón lambda.
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
MX2023012368A (es) Vacuna de virus.
MX2023000881A (es) Estructura genomica del virus de la influenza.
MX2025013140A (es) Composiciones para el uso en el tratamiento del acne
NZ774063A (en) Injectable composition
PH12020500194A1 (en) Malaria vaccine
Meseda et al. Percutaneous vaccination as an effective method of delivery of MVA and MVA-vectored vaccines
ATE435660T1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen